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INTRODUCTION
Systemic chemotherapy is the treatment of choice in patients
with unresectable metastatic colorectal cancer, and although
it is often used with palliative intent, it may be used in an
attempt to achieve a resectable state (1). Adam et al. (1) report-
ed that resectability is successfully attained in only 12.5%
of patients with initially unresectable colorectal hepatic metas-
tases using modern combination chemotherapy.
The in vitro chemosensitivity test (CST) has been used in
an attempt to select patient-specific chemotherapeutic regi-
mens. The response rates seem to be better with in vitro-
selected chemotherapeutic regimens than with empirical
regimens, but the impact on survival has not been adequate-
ly addressed (2). The adenosine triphosphate-based chemother-
apy response assay (ATP-CRA) was verified as a well docu-
mented and validated tool for individualizing chemothera-
py and a survival benefit with this assay-guided chemother-
apy design was observed in patients with unresectable small-
cell lung cancer (3). There are several reports on complete
remission of primary rectal cancer after preoperative chemora-
diation (5, 6); however only a few case reports on colon can-
cer have been published (7).
We describe the first case of a patient, presented with sig-
moid colon cancer with multiple liver and peritoneal metas-
tases, in which there was a complete response for the prima-
ry colon cancer after administration of preoperative chemother-
apy selected by ATP-CRA.
CASE REPORT
A 47-yr-old male was admitted to the hospital for hema-
tochezia associated with a changing pattern of stools for 3
months in August 2005. Colonoscopy revealed an ulcerative,
nearly-obstructing tumor in the sigmoid colon and biopsy
confirmed a moderately differentiated adenocarcinoma. Ab-
dominopelvic computed tomography (CT) (Fig. 1A, 2A)
showed an exophytic tumor mass in the sigmoid colon, with
invasion to the distal left ureter, multiple hepatic metastases
(S8, S7, and S3), and multiple peritoneal seedings. The level
of the serum carcinoembryonic antigen (CEA) was exception-
ally high (12,292 ng/mL).
After deployment of a Hanaro Colorectal Stent� (M.I.Tech,
916
Jung Wook Huh, Yoon Ah Park, 
Eun Joo Jung, Kang Young Lee, 
Ji Eun Kwon*, and Seung-Kook Sohn
Departments of Surgery and Pathology*, Yongdong
Severance Hospital, Yonsei University Health System,
Seoul, Korea
Address for correspondence
Seung-Kook Sohn, M.D.
Department of Surgery, Yongdong Severance 
Hospital, Yonsei University Health System,
146-92 Dogok-dong, Gangnam-gu, Seoul 135-720,
Korea
Tel : +82.2-2019-3370, Fax : +82.2-3462-5994
E-mail : sksohn@yuhs.ac
J Korean Med Sci 2008; 23: 916-9
ISSN 1011-8934
DOI: 10.3346/jkms.2008.23.5.916
Copyright � The Korean Academy
of Medical Sciences
Complete Remission of Unresectable Colon Cancer after Preoperative
Chemotherapy Selected by Adenosine Triphosphate-Based
Chemotherapy Response Assay
The adenosine triphosphate-based chemotherapy response assay (ATP-CRA) is
a chemosensitivity test that offers the potential of selecting cancer treatments based
on the responsiveness of individual tumors. We report a case of 47-yr-old male,
presented with sigmoid colon cancer with multiple liver and peritoneal metastases,
in which there was a complete response for the primary colon cancer after admin-
istration of preoperative chemotherapy selected by ATP-CRA. Oxaliplatin was the
most sensitive drug based on the ATP-CRA where the specimen obtained by ultra-
sound-guided percutaneous liver biopsy was used. After twelve cycles of oxaliplatin-
capecitabine chemotherapy, abdominopelvic computed tomography revealed marked
shrinkage of the liver metastases and positron emission tomography showed no
uptake of 18F-fluoro-deoxy-glucose (FDG) either in the liver or peritoneum except
localized uptake in the sigmoid colon. The patient underwent an anterior resection
and radiofrequency ablation of the liver metastases, which resulted in a macroscop-
ic curative resection of the cancer cells. Histological examination revealed no resid-
ual cancer cells in the resected specimen of the sigmoid colon. This result suggested
that preoperative chemotherapy chosen by ATP-CRA may be useful for treating
advanced colon cancer with unresectable liver and peritoneal metastases.
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Seoul, Korea) and insertion of a double J ureteral stent into
the left ureter for the purpose of palliation, the patient was
submitted for ATP-CRA with an informed consent (8). ATP-
CRA using the patient’s own tumor tissue demonstrated
that oxaliplatin followed by 5-fluorouracil had the highest
cell death rate (CDR), which represents the highest respon-
siveness (3) (Fig. 3). Twelve cycles of oxaliplatin-capecitabine
chemotherapy, as a more convenient regimen for patient,
were scheduled at three-week intervals (4). The patient was
administered intravenous 230 mg (130 mg/m2/day) of oxali-
platin on day 1 every 3 weeks and 1,750 mg (1,000 mg/m2)
of oral capecitabine twice a day on days 1-14 every 3 weeks.
Treatment courses were well tolerated.
Abdominopelvic CT (Fig. 1B, 2B) performed after cycles
3, 6, and 9 revealed the shrinkage of the liver metastases (S8,
10.5 to 3.5 cm; S7, 7.2 to 3.4 cm; S3, 1.7 to 1.5 cm) but no
definite interval change in the sigmoid colon cancer. Positron
emission tomography (PET) (Fig. 4) showed a localized uptake
of 18F-fluoro-deoxy-glucose (FDG) in the sigmoid colon and
no uptake in the liver or peritoneum. The serum CEA was
decreased to 5.1 ng/mL. Because there was a possibility for
curative operation of the sigmoid colon and liver, the patient
underwent an anterior resection, radiofrequency ablation of
the hepatic metastases, and left nephrectomy for hydrone-
phroureter in September 2006, which achieved a macro-
Fig. 1. Multiple liver metastases in sigmoid colon cancer. (A) Before chemotherapy. (B) After chemotherapy.
A B
Fig. 2. Primary sigmoid colon cancer. (A) Before chemotherapy, an exophytic tumor mass (arrow) invading the distal left ureter. (B) After
chemotherapy, a slight decrease in the size of the tumor mass (arrow) but no definite interval change. A Hanaro Colorectal Stent� and a
double J ureteral stent were visible.
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Fig. 3. Tumor suppression rate at peak plasma concentration
(PPC). Longer bars indicate greater in vitro tumor suppression
(p=NS).
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scopic R0 resection. No metastasis to the peritoneum was
detected during the operation. Histological examination
revealed no residual cancer cells in the resected specimen
(CR) (Fig. 5). His last serum CEA level checked in March
2007 was found to be normal (2.2 ng/mL) and the patient
was doing well with no evidence of disease 10 months after
surgery and 25 months after the diagnosis of unresectable
sigmoid colon cancer.
DISCUSSION
The use of systemic chemotherapy in patients with unre-
sectable metastatic colorectal cancer has been traditionally
regarded as a palliative approach. However, it has been thought
of as a neoadjuvant approach to render patients resectable
because of encouraging results of randomized trials using
newly-developed chemotherapeutic agents. For more than
three decades, 5-fluorouracil (5-FU) was the chemotherapeu-
tic agent of choice with a response rate of approximately 20%
(9). Recent chemotherapy combining 5-FU/leucovorin with
either irinotecan or oxaliplatin has been demonstrated superi-
or response rates (31-56%) compared with 5-FU alone (5%)
(10, 11). Tournigand et al. (11) reported response rates of
54 and 56% in patients who received oxaliplatin with 5-FU
(FOLFOX6) and irinotecan with 5-FU (FOLFIRI), respective-
ly. However, they also demonstrated that these high response
rates seen with first-line chemotherapy fell dramatically after
second-line chemotherapy (15% FOLFOX6 and 4% FOL-
FIRI) and the survival for patients who underwent the second-
line chemotherapy was also quite poor. Although these stud-
ies have not focused directly on the primary tumor, the high-
er rates of response and survival of the different combinations
for metastatic lesions suggests that a direct effect on the pri-
mary lesion cannot be excluded. Therefore, chemotherapeu-
tic agents should be carefully chosen because of their critical
effect on the prognosis of the patient. This is the first to report
a complete remission of primary colon cancer after preoper-
ative combination chemotherapy selected by ATP-CRA.
The ATP-CRA is a sensitive assay that evaluates tumor
cell viability by measuring the intracellular ATP levels of
drug-exposed cells and untreated controls (3, 8). Moon et al.
(3) showed good correlations between ATP-CRA results and
clinical outcomes in patients with unresectable lung cancer.
This case report highlights a new and different perspective
in the management of patients with unresectable metastatic
colorectal cancer. It is suggested that preoperative chemother-
apy regimen chosen by ATP-CRA may be useful for treat-
ing these patients, although the results of in vitro CST only
validated the use of the same set of drugs that would have
been selected on the basis of the clinical trial literature (12).
Fig. 5. Histological features of sigmoid colon cancer. (A) Before chemotherapy, a biopsy of the lesion showed adenocarcinoma (H&E
×200). (B) No residual cancer cells were present in the resected specimen (CR) (H&E ×40).
A B
Fig. 4. After chemotherapy, PET scan showed a localized uptake
of 18F-fluoro-deoxy-glucose (FDG) and no uptake in the liver or peri-
toneum.
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Further good correlations between ATP-CRA results and
clinical outcomes are warranted.
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